Government Contracting
A trusted partner in the procurement of essential medications, medical devices, and active pharmaceutical ingredients necessary for the manufacturing of final products is delineated within our North American Industry Classification System (NAICS) codes relevant to our operations with the Federal Government. The applicable codes are as follows: 424210, 541611, 423450, 352412, 334510, 339113, 541380, and 541690.
Pharmaceutical and Medical Professionals
We provide expert advisory and research services aimed at fortifying pharmaceutical and medical device supply chains through robust regulatory compliance, strategic sourcing, and comprehensive market intelligence. Our offerings include actionable insights, white papers, and alternative sourcing strategies designed to augment supply chain resilience and facilitate informed decision-making for both government and healthcare stakeholders.
Advisory Services and Market Analysis
Extensive expertise in therapeutics, regulatory compliance, sourcing strategies, and market dynamics, we enable clients to make informed decisions through meticulous market research and data-driven projections.
Example Request from a Customer
The Dominance of Generic Drugs in the U.S. Prescription Market
Top Generic Prescription Medications in the U.S. (Estimated 2024)
The chart illustrates the estimated prescription volume for the top generic medications dispensed in the United States in 2024, underscoring the nation’s continued reliance on high-demand, cost-effective generics.
Levothyroxine leads the market in volume with approximately 99 million prescriptions, reflecting its widespread use in managing thyroid disorders. Metformin follows closely at 92.6 million, maintaining its position as the most prescribed medication for type 2 diabetes. Lisinopril ranks third with 88.6 million prescriptions, consistent with its role in hypertension and cardiovascular care.
Other commonly dispensed agents include Amlodipine (69.8M) and Metoprolol (66.4M), both key antihypertensives, as well as Albuterol (62M), a mainstay in respiratory disease management. Gastrointestinal and cardiovascular categories are also represented through Omeprazole (56.3M) and Losartan (54.8M). Finally, Gabapentin (50M) highlights the growing utilization of neurological and pain-management therapies.
Collectively, these figures reflect the dominance of chronic disease therapies—particularly cardiovascular, metabolic, endocrine, and neurological—within the U.S. prescription landscape. Generic medications continue to represent over 90% of all prescriptions filled nationwide, emphasizing their critical role in ensuring medication accessibility, affordability, and supply chain resilience.
Get in Touch
We invite you to reach out to us to gain further insights into our pharmaceutical and medical device distribution services, as well as our market research initiatives focused on pharmaceuticals, active pharmaceutical ingredients, and medical devices.
